Kerna Ventures·Jun 2In Vivo CAR-T and B-Cell Depletion: Where to Next?Autologous CAR-T has demonstrated incredible efficacy in both oncology and autoimmune disease, bringing a disease-modifying and even…
Kerna Ventures·Nov 3, 2025Blood-Brain Barrier Hitchhikers: The Future of CNS TherapeuticsOwing to the blood-brain barrier’s (BBB) relative impermeability, biologics and oligonucleotide-based drugs have restricted CNS…
Kerna Ventures·Sep 1, 2025The Biggest Losers: Obesity Therapeutics LandscapeGLP-1 has transformed the therapeutic landscape, with Novo’s Semaglutide and Lilly’s Tirzepatide becoming…A response icon1A response icon1
Kerna Ventures·Jun 1, 2025Inside Big Pharma: What 16 Giants Are Betting On NextDynamics of 16 selected big pharma companies with their R&D and partnership pipelines…
Kerna Ventures·Mar 1, 2025The In Vivo CAR-T RaceCAR immunotherapy has transformed outcomes in hematological cancers. Now over 30 companies are racing to develop in vivo CAR therapies…
Kerna Ventures·May 1, 2024Pioneers of Promise: Top 40 in Gene DeliveryEven as numerous gene therapies clear regulatory hurdles, one obstacle continues to cast a shadow over progress: delivery.
Kerna Ventures·Dec 17, 2023Gene Editing — Now FDA-blessed.In December 2023, the CRISPR/Cas9 gene editing therapy, known as exa-cel, received FDA approval.
Kerna Ventures·May 30, 2023Generative AI: Hype & BeyondOur aim this time was to look at the underside of the generative AI iceberg..
Kerna Ventures·Apr 13, 2023Trillions Within Us: The Microbiome First UnicornsAs humans, we often think of ourselves as solitary entities, with our thoughts and actions driven solely by our own decisions...
Kerna Ventures·Apr 12, 2023From Kernel to RNA: the Story Behind Kerna VenturesAt Kerna Ventures, we are driven by a passion for innovation in physics, biology, and computer science...
